TEVA EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
TEVA's ev/ebitda is higher than 82% of the last 10 years.
EV/EBITDA History
TEVA EV/EBITDA by year
Yearly range of TEVA’s ev/ebitda from 2016 to 2026. Over the full period it ranged from 7.4 to 53.8, averaging 17.8.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 14.6 | 17.5 | 22.4 | 21.8 |
| 2025 | 10.0 | 14.8 | 23.8 | 16.0 |
| 2024 | 7.4 | 13.0 | 23.8 | 23.8 |
| 2023 | 13.7 | 20.7 | 40.7 | 16.5 |
| 2022 | 9.9 | 15.6 | 18.9 | 18.6 |
| 2021 | 8.0 | 8.4 | 10.2 | 10.2 |
| 2020 | 13.0 | 17.9 | 21.9 | 13.1 |
| 2019 | 19.7 | 50.6 | 53.8 | 19.7 |
| 2018 | 48.5 | 48.5 | 48.5 | 48.5 |
| 2017 | 20.7 | 22.1 | 23.7 | 22.4 |
| 2016 | 9.5 | 15.0 | 17.3 | 15.3 |
Get notified when TEVA EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is TEVA EV/EBITDA High or Low Right Now?
Teva Pharmaceutical Industries Limited's EV/EBITDA is currently 21.8, which is historically pricey relative to its 10-year historical range. The 10-year median EV/EBITDA for TEVA is approximately 15.9. See all TEVA valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.